Serum metabolomics to identify molecular subtypes and predict XELOX efficacy in colorectal cancer.

ABSTRACT: Colorectal cancer (CRC) is one of the most common cancers; however, accurately predicting prognosis based on existing molecular subtypes remains challenging. The XELOX regimen, which combines oxaliplatin and capecitabine, is the cornerstone of chemotherapy for CRC treatment. However, there is a notable lack of reliable predictive models for determining the sensitivity of this treatment. This study aimed to establish a novel classification system for CRC and develop a predictive model for XELOX chemotherapeutic sensitivity using serum metabolomics. We recruited 89 patients with CRC and 89 age- and sex-matched healthy controls for untargeted metabolomic studies to identify tumor-specific serum metabolites. The patients were grouped into distinct metabolic subtypes using unsupervised clusteri

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC12012017 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature